GlassScriptPhysician profile
Ashley J Castle
NPI 1083993760
$10,576.49
in general payments reported to CMS, 2019-2025
52 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,126 · 2022: $2,390 · 2023: $2,062 · 2024: $1,871 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,060.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,652.84 | 2021-2025 | |
| Novo Nordisk INC | $1,238.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $914.54 | 2021-2025 | Rexulti |
| Pfizer INC. | $721.98 | 2021-2025 | |
| Lilly USA, LLC | $470.49 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $393.27 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $334.23 | 2021-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $317.87 | 2021-2023 | Belsomra, Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $311.89 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $296.04 | 2021-2023 | Nexletol |
| Astellas Pharma US INC | $281.00 | 2022-2025 | Veozah |
| Axsome Therapeutics, INC. | $271.12 | 2023-2025 | Auvelity, Sunosi |
| Dynavax Technologies Corporation | $242.35 | 2024-2025 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $213.74 | 2021-2025 | Trintellix |
| Nestle Healthcare Nutrition INC. | $209.63 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Castle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.